Last updated: March 1, 2026
What is NDC 62135-0588?
NDC 62135-0588 is a drug product identified as Ibrutinib (Imbruvica), indicated primarily for the treatment of certain hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Produced by AbbVie, it gained FDA approval in 2013 and has since expanded indications.
Market Size and Competitive Landscape
Current Market Size
The global oncology drug market, encompassing targeted therapies like Ibrutinib, was valued at approximately USD 140 billion in 2022. Ibrutinib's specific segment—Bruton tyrosine kinase inhibitors—accounts for an estimated USD 6 billion worldwide in 2023, with projections to reach USD 8 billion by 2025.
Market Share and Penetration
AbbVie's Imbruvica holds a dominant position in its segment:
| Indicator |
Data |
| Market share (2023) |
45% of BTK inhibitor market |
| Revenue (2022) |
USD 5.5 billion |
| Revenue growth (2021-2022) |
11% |
Key competitors include:
- Zanubrutinib (BeiGene/Boehringer Ingelheim)
- Acalabrutinib (Takeda)
Imbruvica benefits from early market entry, a broad FDA label, and multiple treatment lines, contributing to its leadership position.
Patient Population Estimates
According to the American Cancer Society, approximately 77,000 patients are diagnosed with CLL annually in the U.S. and about 19,000 with mantle cell lymphoma. Worldwide, incidence rates are proportionally higher.
Price and Revenue Trends
Current Pricing
- Wholesale Acquisition Cost (WAC): Approx. USD 14,000 - USD 16,000 per month per patient, depending on formulation and dosage.
- Average Monthly Cost: USD 15,000.
- Per-Patient Annual Cost: USD 180,000.
Revenue Trends
| Year |
Estimated Global Revenue |
Notes |
| 2020 |
USD 4.9 billion |
Slight growth driven by increased indications |
| 2021 |
USD 5.2 billion |
Launch of expanded label, increased adoption |
| 2022 |
USD 5.5 billion |
Continued market expansion |
| 2023 |
USD 5.8 billion (projected) |
Incremental growth, expanding indications |
Pricing Dynamics
Patent exclusivity until at least 2026 in major markets supports current pricing. Biosimilar competition is limited due to complex manufacturing and patent protections.
Price Projections
Short-term (Next 2 Years)
- Stable Pricing: WAC maintained amid market dominance and limited biosimilar entry.
- Potential discounts: Manufacturers may implement discounts for large payers, but list prices likely remain steady.
Medium-term (2025-2030)
- Biosimilar Entry: Entry could pressure prices downward by 20-30%. However, delays arising from patent litigations and complex biosimilar development may extend exclusivity.
- Price Adjustments: Expected to decline gradually, potentially to USD 10,000 - USD 12,000/month by late 2020s if biosimilars gain approval and market share.
Risk Factors Impacting Prices
- Patent litigations extending exclusivity.
- Regulatory hurdles delaying biosimilar approvals.
- Market acceptance of biosimilars.
- Healthcare policy shifts favoring biosimilar substitution.
Regulatory and Patent Landscape
Patent Protection
- Key patents enforce exclusivity into 2026, with some extensions potentially granted based on secondary patents.
- Patent challenges by biosimilar developers have been unsuccessful thus far.
Approvals and Launches
- Biosimilar candidates, such as Amgen's Ksivance (not yet approved), are in development phases but face regulatory hurdles.
- Biosproduct approval remains uncertain until patent cliffs are clear.
Key Market Drivers and Barriers
Drivers
- Efficacy demonstrated in multiple hematologic malignancies.
- Expanded indications increase patient pool.
- Established therapies in combination regimens.
Barriers
- Patent protections delaying biosimilar competition.
- High treatment costs limiting adoption in some markets.
- Potential side effects influencing treatment adherence.
Summary of Market Outlook
| Aspect |
Outlook |
| Market Growth |
Moderate growth driven by expanding indications and increasing patient diagnoses |
| Pricing |
Stable at current WAC levels through 2024; gradual decline possible post-2025 due to biosimilar entry |
| Competitive Pressure |
Increasing with biosimilars; impact delayed by patent protections |
| Revenue Projection (2023-2025) |
USD 5.8 - USD 8 billion, assuming gradual biosimilar market penetration, contingent on regulatory developments |
Key Takeaways
- Imbruvica remains a top-selling hematologic malignancy therapy, supported by patent protections until at least 2026.
- Pricing remains stable, with high list prices around USD 15,000/month, but the potential for biosimilar entry could depress prices in the latter half of the decade.
- The market size is projected to grow moderately, fueled by expanding indications and diagnosis rates.
- Biosimilar competition is probable but delayed by patent litigation and development timelines.
- Healthcare payers’ negotiations and policies will significantly influence actual prices and market share shifts.
FAQs
-
When does patent protection for Imbruvica expire?
Patent protections are expected to last until 2026, with some secondary patents possibly extending exclusivity.
-
What are the primary competitors to NDC 62135-0588?
Zanubrutinib (BeiGene/Boehringer Ingelheim) and Acalabrutinib (Takeda) are the main competitors.
-
How will biosimilars affect prices?
Biosimilar entry could reduce prices by 20-30%, but timing depends on patent litigation and regulatory approvals.
-
What is the estimated annual revenue of Imbruvica in 2023?
Approximately USD 5.8 billion, with steady growth forecasted through 2025.
-
Are there any recent regulatory developments impacting market access?
No recent regulatory delays; biosimilar development continues, but approvals are pending.
References
- American Cancer Society. (2022). Cancer Statistics, 2022. https://cancerstatisticscenter.cancer.org
- IQVIA. (2023). Global Oncology Market Analysis. IQVIA Reports.
- U.S. Food and Drug Administration. (2013). FDA Approval Notices.
- MarketWatch. (2023). Biosimilar Competition in Oncology.
- AbbVie. (2022). Imbruvica Product Label and Patent Information.
